Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roquefort Investments PLC ( (GB:ROQ) ) just unveiled an update.
Roquefort Therapeutics PLC has successfully raised £300,000 to fund the upfront costs of a proposed transaction with A2A Pharmaceuticals and Coiled Therapeutics. This transaction will grant Roquefort exclusive license rights to AO-252, a new drug targeting the TACC3 protein for cancer treatment. The fundraising includes £200,000 from strategic investors and a £100,000 loan from A2A Pharmaceuticals. The completion of this transaction is expected to enhance Roquefort’s position in the biotech industry by expanding its portfolio of cancer treatments and demonstrating strong support from key stakeholders.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market of the London Stock Exchange. The company focuses on developing innovative treatments for cancer, with a particular emphasis on acquiring exclusive rights to novel drug alternatives. Their market focus includes strategic collaborations with other pharmaceutical entities to enhance their therapeutic offerings.
Average Trading Volume: 2,213,745
Technical Sentiment Signal: Sell
Current Market Cap: £3.31M
See more data about ROQ stock on TipRanks’ Stock Analysis page.